BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Drug Approval

Alebund Pharmaceuticals Receives FDA Orphan Drug Designation for AP303 in ADPKD Treatment

Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for th...

April 01, 2024 | News

FDA Approves Vafseo for Anemia in Dialysis Patients

SL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) ...

March 29, 2024 | News

MSD announces FDA approval of WINREVAIR™ for pulmonary arterial hypertension, introducing a novel class of therapy.

MSD, also known in the United States and Canada as Merck (NYSE: MRK), announced today the U.S. Food and Drug Administration (FDA) has granted approval for ...

March 27, 2024 | News

DigmBio's Breakthrough Cancer Drug Clears Korean Regulatory Hurdle

BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breas...

March 26, 2024 | News

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) is plea...

March 25, 2024 | News

Vertex Pharmaceuticals Receives FDA Clearance for Innovative ADPKD Drug Trial

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) f...

March 22, 2024 | News

Oscotec Inc. Gains FDA Orphan Drug Designation for Promising ITP Treatment Cevidoplenib

Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immun...

March 22, 2024 | News

Singapore Approves Everest Medicines' NEFEGAN® for Adult Primary IgA Nephropathy

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, development, manufacturing and commerc...

March 20, 2024 | News

KeChow Pharma's Tunlametinib Receives Historic Approval in China for Advanced Melanoma Treatment

KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule therapeutics for cancer, t...

March 19, 2024 | News

FDA Grants Fast Track Designation to ImmVira's MVR-T3011 IT for Advanced Head and Neck Cancer

ImmVira's groundbreaking oncolytic virus therapy, MVR-T3011 IT intratumoral injection, has been awarded Fast Track designation by the U.S. Food and Drug Ad...

March 18, 2024 | News

CStone's Sugemalimab Granted Historic Approval in China for Gastric Cancer Treatment

CStone Pharmaceuticals has achieved a significant milestone with the approval of sugemalimab (Cejemly®) by the National Medical Products Administration...

March 18, 2024 | News

BeiGene's TEVIMBRA Wins FDA Nod for Advanced Esophageal Cancer Post-Chemotherapy

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has app...

March 15, 2024 | News

FDA Approves Rezdiffra for Noncirrhotic NASH with Liver Fibrosis

U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with m...

March 15, 2024 | News

Mirum Pharmaceuticals Announces FDA Approval of LIVMARLI for Cholestatic Pruritus in PFIC Patients

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leader in developing innovative treatments for rare liver diseases, has proudly announced the...

March 14, 2024 | News

Stay Connected